4D Molecular Therapeutics FDMT Operating Lease ROU Assets
Operating Lease ROU Assets at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's operating lease rou assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's operating lease ROU assets?
- 4D Molecular Therapeutics (FDMT) reported operating lease ROU assets of $17.36M in Q1 2026.
- How has 4D Molecular Therapeutics's operating lease ROU assets changed year-over-year?
- 4D Molecular Therapeutics's operating lease ROU assets decreased by 14.8% year-over-year, from $20.37M to $17.36M.
- What is the long-term trend for 4D Molecular Therapeutics's operating lease ROU assets?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's operating lease ROU assets has grown at a 1.9% compound annual growth rate (CAGR), from $16.5M to $18.14M.
- What does operating lease ROU assets mean?
- This asset represents the company's right to use a leased item, such as office space or data center facilities, over the lease term. It is recognized under modern accounting standards to reflect the financial commitment of long-term operating leases. It provides visibility into the company's fixed operational footprint.